| Symbol | COCP |
|---|---|
| Name | COCRYSTAL PHARMA, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 19805 NORTH CREEK PARKWAY, BOTHELL, Washington, 98011, United States |
| Telephone | +1 786 459-1831 |
| Fax | — |
| — | |
| Website | https://www.cocrystalpharma.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001412486 |
| Description | Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. The company employs structure-based technologies and Nobel Prize-winning expertise to create first-and best-in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI). Additional info from NASDAQ: |
(99% Neutral) COCRYSTAL PHARMA, INC. (COCP) Announces New Board Appointment
Read moreSAPIRSTEIN JAMES 🟢 acquired 235.0K shares (1 derivative) of Cocrystal Pharma, Inc. (COCP) at $1.12 Transaction Date: Jun 03, 2026 | Filing ID: 027054
Read moreNew Form 3 - Cocrystal Pharma, Inc. <b>Filed:</b> 2026-06-03 <b>AccNo:</b> 0001493152-26-027053 <b>Size:</b> 17 KB
Read moreCocrystal Pharma Appoints James Sapirstein, Biopharma Industry Leader with Extensive Antiviral Development Experience, as Chief Executive Officer
Read more(10% Negative) COCRYSTAL PHARMA, INC. (COCP) Announces Delay in need Trials for many years Due to Geopolitical Situation, Regulatory Process, Manufacturing Considerations, Safety Review
Read moreCocrystal Pharma Appoints James Sapirstein, Biopharma Industry Leader with Extensive Antiviral Development Experience, as Chief Executive Officer
Read moreNew Form DEFA14A - Cocrystal Pharma, Inc. <b>Filed:</b> 2026-05-27 <b>AccNo:</b> 0001493152-26-025430 <b>Size:</b> 57 KB
Read moreNew Form DEF 14A - Cocrystal Pharma, Inc. <b>Filed:</b> 2026-05-27 <b>AccNo:</b> 0001493152-26-025428 <b>Size:</b> 1 MB
Read more(10% Negative) COCRYSTAL PHARMA, INC. (COCP) Announces Delay in development Development Timeline Due to Geopolitical Situation, Pandemic-Related Challenges, Regulatory Process, Manufacturing Considerations, Safety Review
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07198139 | A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CDI-988 in Hea… | Phase1 | Norovirus | Recruiting | 2026-03-01 | 2026-12-01 | ClinicalTrials.gov |
| NCT06160531 | Influenza Viral Challenge Study of CC-42344 in Healthy Participants | Phase2 | Influenza A | Completed | 2023-11-25 | 2024-07-18 | ClinicalTrials.gov |
| NCT05977140 | CDI-988 Safety Study in Healthy Participants | Phase1 | Healthy Volunteers | Completed | 2023-09-27 | 2025-07-23 | ClinicalTrials.gov |
| NCT05202379 | CC-42344 Safety Study in Healthy Participants | Phase1 | Influenza A | Completed | 2022-02-11 | 2023-03-29 | ClinicalTrials.gov |
| NCT03501550 | Study of CDI-31244 in Combination With Sofosbuvir (SOF) and Velpatasvir (VEL) | Phase2 | Chronic Hepatitis C | Completed | 2018-06-26 | 2019-06-07 | ClinicalTrials.gov |
| NCT02760758 | A Study of CDI-31244: A Novel NNI in HV and HCV Infected Subjects | Phase1 | Hepatitis C | Completed | 2016-04-01 | 2017-04-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Placebo | Other | Phase PHASE1 | Hepatitis C | COMPLETED | NCT02760758 |
| CDI-31244 | Other | Phase PHASE1 | Hepatitis C | COMPLETED | NCT02760758 |
| SOF/VEL | Other | Phase PHASE2 | Chronic Hepatitis C | COMPLETED | NCT03501550 |
| CDI-31244 | Other | Phase PHASE2 | Chronic Hepatitis C | COMPLETED | NCT03501550 |
| Placebo | Other | Phase PHASE2 | Influenza A | COMPLETED | NCT06160531 |
| CC-42344 | Other | Phase PHASE2 | Influenza A | COMPLETED | NCT06160531 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05977140 |
| CDI-988 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05977140 |
| Snow Mountain Virus | Other | Phase PHASE1 | Norovirus | RECRUITING | NCT07198139 |
| Placebo | Other | Phase PHASE1 | Norovirus | RECRUITING | NCT07198139 |
| CDI-988 | Other | Phase PHASE1 | Norovirus | RECRUITING | NCT07198139 |
| Placebo | Other | Phase PHASE1 | Influenza A | COMPLETED | NCT05202379 |
| CC-42344 | Other | Phase PHASE1 | Influenza A | COMPLETED | NCT05202379 |
| Snow Mountain Virus | OTHER | Phase PHASE1 | Norovirus | RECRUITING | NCT07198139 |
| CDI-988 | DRUG | Phase PHASE1 | Norovirus | RECRUITING | NCT07198139 |
| CC-42344 | DRUG | Phase PHASE2 | Influenza A | COMPLETED | NCT06160531 |
| SOF/VEL | DRUG | Phase PHASE2 | Chronic Hepatitis C | COMPLETED | NCT03501550 |
| Placebo | DRUG | Phase PHASE1 | Norovirus | RECRUITING | NCT07198139 |
| CDI-31244 | DRUG | Phase PHASE2 | Chronic Hepatitis C | COMPLETED | NCT03501550 |